PDF herunterladen
CC BY-NC-ND 4.0 · Avicenna J Med 2020; 10(04): 135-162
DOI: 10.4103/ajm.ajm_171_20
Review Article

Palestinian strategies, guidelines, and challenges in the treatment and management of coronavirus disease-2019 (COVID-19)

Hatem A Hejaz
College of Pharmacy & Medical Sciences, Hebron University, Hebron, Palestine
› Institutsangaben
Verantwortlicher Herausgeber dieser Rubrik: Financial support and sponsorship Nil.
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Background: Coronavirus disease-2019 (COVID-19) outbreak is a global concern and the World Health Organization (WHO) has declared it as a Public Health Emergency of International Concern. The Palestinian Authority (PA) has quickly and effectively responded to the outbreak of COVID-19, using an internationally and nationally coordinated, to contain the spread of the virus within the borders. The PA approaches are containment and suppression, which is designed to protect the citizens from infection while also mitigating the stress on the health care system. The PA immediately declared a State of Emergency when the first cases in Palestine were diagnosed on 5 March 2020 and launched robust national containment measures to encourage the citizens to protect themselves and follow the guidance. Objectives: There is currently no vaccine or effective treatment for COVID-19, the treatment is either supportive and/ or the treatment of symptoms. Several strategies in the treatment of the disease were applied including medications. This review aims to summarize the different strategies, guidelines, challenges, and treatments used against COVID-19 worldwide and in Palestine. Materials and Methods: Different literature and guidelines among different databases were searched. Literature reviewing was conducted using the following search engines, Google Scholar, Medline, Pub Med, EMBASE, Web of Science, and Science Direct. Data also obtained from WHO and PA reports, and the published peer-reviewed articles of 2019-nCoV. The review focuses on the strategies, guidelines, therapeutics, challenges, and different approaches used in the treatment and management of the disease in Palestine and globally. Conclusion: The Palestinian Ministry of Health (MoH) strategies to end the COVID-19 pandemic were; slow and stop transmission; provide optimized care for patients; and minimize the impact of the epidemic on health systems, social services, and economic activity. Thus, proper management, right actions, and effective treatment of the disease should be considered to achieve these strategies. The biggest problem for PA to control and stop the outbreak of the disease is the different challenges which include; the Israeli military and economic control, uncontrol the borders, shortage of medical and financial resources, crowded cities and refugee camps, poverty, food insecurity, and the financial crisis. To date, there are no specific vaccines or medicines for COVID-19; and treatments are under investigation through clinical trials. However, an array of drugs approved for other indications, as well as multiple investigational agents, are being studied for the treatment of COVID-19; in several hundred clinical trials around the World. Treatment is essentially supportive and symptomatic.

Keywords

2019-nCoV - challenges - coronavirus - COVID-19 - Palestine - treatment


Publikationsverlauf

Artikel online veröffentlicht:
04. August 2021

© 2020. Syrian American Medical Society. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 World Health Organization. Coronavirus Disease (COVID-2019) Situation Reports. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/. [Last accessed on 2020 Apr 9]
    Google Scholar
  • 2 Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19): Cases in U.S. 2020 Available from: https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html. [Last accessed on 2020 Apr 9]
    PubMedGoogle Scholar
  • 3 Richman DD, Whitley RJ, Hayden FG. Clinical Virology. 4th ed. Washington, DC: ASM Press; 2016
    CrossrefGoogle Scholar
  • 4 United Nations (UA). Occupied Palestinian Territory. COVID-19 Emergency Situation Report 6. 2020 Available from: https://www.ochaopt.org/content/covid-19-emergency-situation-report-6. [Last accessed on 2020 Apr 21–28]
    PubMedGoogle Scholar
  • 5 United Nations (UA). Occupied Palestinian Territory. COVID-19 Emergency Situation Report 11. 2020 Available from: https://www.ochaopt.org/content/covid-19-emergency-situation-report-11. [Last accessed on 2020 Jun 3–16]
    PubMedGoogle Scholar
  • 6 United Nations (UN). The Question of Palestine. Coronavirus Disease 2019 (COVID-19) WHO Update 16; 2020c. Occupied Palestinian territory (epidemiological week 5). Available from: https://www.un.org/unispal/document/coronavirus-disease-2019-covid-19-update-16/. [Last accessed on 2020 Mar 3]
    Google Scholar
  • 7 Singhal T. A review of coronavirus disease-2019 (COVID-19). Indian J Pediatr 2020; 87: 281-6
    CrossrefPubMedGoogle Scholar
  • 8 Guan WJ, Ni ZY, Hu Y. et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382: 1708-20
    CrossrefPubMedGoogle Scholar
  • 9 Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR. et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: Estimation and application. Ann Intern Med 2020; 172: 577-82
    CrossrefPubMedGoogle Scholar
  • 10 Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72,314 cases From the Chinese Center for Disease Control and Prevention. JAMA 2020. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32091533
  • 11 Garg S, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R. et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 - COVID-NET, 14 states, march 1-30, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 458-64
    CrossrefPubMedGoogle Scholar
  • 12 Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C. et al. Transmission of 2019-ncov infection from an asymptomatic contact in germany. N Engl J Med 2020; 382: 970-1
    CrossrefPubMedGoogle Scholar
  • 13 Yu P, Zhu J, Zhang Z, Han Y, Huang L. A familial cluster of infection associated with the 2019 novel coronavirus indicating potential person-to-person transmission during the incubation period. J Infect Dis 2020. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32067043
  • 14 Bai Y, Yao L, Wei T. et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA 2020. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32083643
  • 15 Wu C, Chen X, Cai Y. et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32167524
  • 16 Cai Q, Chen F, Luo F. et al. Obesity and COVID-19 severity in a designated hospital in Shenzhen, China. Lancet 2020. Available from: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3556658
  • 17 Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19): People Who Are at Higher Risk for Severe Illness. 2020 Available from: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-at-higher-risk.html [Last accessed on 2020 Apr 8]
    PubMedGoogle Scholar
  • 18 Shi H, Han X, Jiang N. et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: A descriptive study. Lancet Infect Dis 2020; 20: 425-34
    CrossrefPubMedGoogle Scholar
  • 19 Hellewell J, Abbott S, Gimma A, Bosse NI, Jarvis CI, Russell TW. et al Centre for the Mathematical Modelling of Infectious Diseases COVID-19 Working Group. Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts. Lancet Glob Health 2020; 8: e488-96
    CrossrefPubMedGoogle Scholar
  • 20 AlKhaldi M, Kaloti R, Shella D, Al Basuoni A, Meghari H. Health system’s response to the COVID-19 pandemic in conflict settings: Policy reflections from Palestine. Int J Res Policy Pract 2020; 15: 1244-56
    Google Scholar
  • 21 Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P. et al. Genome composition and divergence of the novel coronavirus (2019-ncov) originating in china. Cell Host Microbe 2020; 27: 325-8
    CrossrefPubMedGoogle Scholar
  • 22 Wu J, Liu J, Zhao X, Liu C, Wang W, Wang D. et al. Clinical characteristics of imported cases of covid-19 in Jiangsu province: A multicenter descriptive study. Clin Infect Dis 2020
  • 23 Wu Z, Mcgoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323: 1239-42
    CrossrefPubMedGoogle Scholar
  • 24 WHO. 2020 Clinical Management of Severe Acute Respiratory Infection when Novel Coronavirus (nCoV) Infection is Suspected. Interim guidance 2020 Published on January 28
    PubMed
  • 25 Alhazzani W, Alshamsi F, Belley-Cote E, Heels-Ansdell D, Brignardello-Petersen R, Alquraini M. et al. Efficacy and safety of stress ulcer prophylaxis in critically ill patients: A network meta-analysis of randomized trials. Intensive Care Med 2018; 44: 1-11
    CrossrefPubMedGoogle Scholar
  • 26 Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-ncov lung injury. Lancet 2020; 395: 473-5
    CrossrefPubMedGoogle Scholar
  • 27 Yoshikawa TT, High K. Nutritional strategies to boost immunity and prevent infection in elderly individuals. Clin Infect Dis 2001; 33: 1892-900
    CrossrefPubMedGoogle Scholar
  • 28 Nonnecke BJ, McGill JL, Ridpath JF, Sacco RE, Lippolis JD, Reinhardt TA. Acute phase response elicited by experimental bovine diarrhea virus (BVDV) infection is associated with decreased vitamin D and E status of vitamin-replete preruminant calves. J Dairy Sci 2014; 97: 5566-79
    CrossrefPubMedGoogle Scholar
  • 29 Reardon Sara. Antibiotic treatment for COVID-19 complications could fuel resistant bacteria. Science’s COVID-19 reporting is supported by the Pulitzer Center. Health Coronavirus; DOI: 10.1126/science.abc2995
    CrossrefGoogle Scholar
  • 30 Zhang LY. Potential interventions for novel coronavirus in China: A systemic review. J Med Virol 2020; 92: 479-90
    CrossrefPubMedGoogle Scholar
  • 31 Xu XWXW, Jiang XG. et al. “Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: Retrospective case series. BMJ 2020; 368: m606
    PubMedGoogle Scholar
  • 32 Zhang W. et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clin Immunol 2020; 214: 108393
    CrossrefPubMedGoogle Scholar
  • 33 Jin YHCL, Cheng ZS. et al. “A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus [2019-nCoV] infected pneumonia”. Mil Med Res 2020; 7: 4
    PubMedGoogle Scholar
  • 34 Li G, Chen X, Xu A. Profile of specific antibodies to the SARS-associated coronavirus. N Engl J Med 2003; 349: 508-9
    CrossrefPubMedGoogle Scholar
  • 35 Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-ncov) in vitro. Cell Res 2020; 30: 269-71
    CrossrefPubMedGoogle Scholar
  • 36 Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: What to expect for COVID-19?. Int J Antimicrob Agents 2020; 55: 105938
    CrossrefPubMedGoogle Scholar
  • 37 Cortegiani A, Ippolito M, Ingoglia G, Iozzo P, Giarratano A, Einav S, Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19. J Crit Care 2020; 59: 176-90
    CrossrefPubMedGoogle Scholar
  • 38 US Food and Drug Administration. Letter of Authorization: Emergency Use Authorization for Use of Chloroquine Phosphate or Hydroxychloroquine Sulfate Supplied from the Strategic National Stockpile for Treatment of 2019 Coronavirus Disease. 2020 Mar 28. Available from: https://www.fda.gov/media/136534/download
    PubMedGoogle Scholar
  • 39 Sahraei Z, Shabani M, Shokouhi S, Saffaei A. Aminoquinolines against coronavirus disease 2019 (COVID-19): Chloroquine or hydroxychloroquine. Int J Antimicrob Agents 2020; 55: 105945
    CrossrefPubMedGoogle Scholar
  • 40 National Institutes of Health. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Updated 2020 Jul 17. Available from: https://www.covid19treatmentguidelines.nih.gov/. [Last accessed on 2020 Jul 21]
    Google Scholar
  • 41 Williamson BN, Feldmann F, Schwarz B. et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature 2020 Jun 9 [Epub ahead of print]. PMID: 32516797. doi: 10.1038/s41586-020-2423-5
  • 42 Gilead Sciences. Emergency Access to Remdesivir Outside of Clinical Trials. Available from: https://www.gilead.com/purpose/advancing-global-health/covid-19/emergency-access-to-remdesivir-outside-of-clinical-trials. [Last accessed on 2020 May 24]
    Google Scholar
  • 43 Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ. et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-cov. Nat Commun 2020; 11: 222
    CrossrefPubMedGoogle Scholar
  • 44 Chu CM, Chan VL, Lin AW, Wong IW, Leung WS, Lai CK. Readmission rates and life threatening events in COPD survivors treated with non-invasive ventilation for acute hypercapnic respiratory failure. Thorax 2004; 59: 1020-5
    CrossrefPubMedGoogle Scholar
  • 45 Cao B. et al. A trial of Lopinavir–Ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020; 382: 1787-99
    CrossrefPubMedGoogle Scholar
  • 46 Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ. et al. Case of the index patient who caused tertiary transmission of COVID-19 infection in korea: The application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci 2020; 35: e79
    CrossrefPubMedGoogle Scholar
  • 47 Meynard JL, Moinot L, Landman R, Morand-Joubert L, Besseghir A, Kolta S. et al ANRS 140 DREAM Study Group. Week 96 efficacy of lopinavir/ritonavir monotherapy in virologically suppressed patients with HIV: A randomized non-inferiority trial (ANRS 140 DREAM). J Antimicrob Chemother 2018; 73: 1672-6
    CrossrefPubMedGoogle Scholar
  • 48 Van Der Laan LE, Garcia-Prats AJ, Schaaf HS, Tikiso T, Wiesner L, DE Kock M. et al. Pharmacokinetics and drug-drug interactions of lopinavir-ritonavir administered with first-and second-line antituberculosis drugs in HIV-infected children treated for multidrug-resistant tuberculosis. Antimicrob Agents Chemother 2018; 62: e00420-17
    CrossrefPubMedGoogle Scholar
  • 49 Chan JF, Yao Y, Yeung ML, Deng W, Bao L, Jia L. et al. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-cov infection in a nonhuman primate model of common marmoset. J Infect Dis 2015; 212: 1904-13
    CrossrefPubMedGoogle Scholar
  • 50 Crotty S, Cameron C, Andino R. Ribavirin’s antiviral mechanism of action: Lethal mutagenesis?. J Mol Med (Berl) 2002; 80: 86-95
    CrossrefPubMedGoogle Scholar
  • 51 Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad-spectrum inhibitor of viral RNA polymerase. Proc Japan Acad B 2017; 93: 449-63
    CrossrefPubMedGoogle Scholar
  • 52 Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Res 2018; 153: 85-94
    CrossrefPubMedGoogle Scholar
  • 53 Kadam RU, Wilson IA. Structural basis of influenza virus fusion inhibition by the antiviral drug arbidol. Proc Natl Acad Sci USA 2017; 114: 206-14
    CrossrefPubMedGoogle Scholar
  • 54 Khamitov RA, Loginova SIa, Shchukina VN, Borisevich SV, Maksimov VA, Shuster AM. Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures. Vopr Virusol 2008; 53: 9-13
    PubMedGoogle Scholar
  • 55 Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical features of 69 cases with coronavirus disease 2019 inWuhan, China. Clin Infect Dis 2020; DOI: 10.1093/cid/ciaa272.
    CrossrefPubMedGoogle Scholar
  • 56 Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Therap 2020; 14: 58-60
    Google Scholar
  • 57 Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther 2020; 14: 58-60
    CrossrefPubMedGoogle Scholar
  • 58 Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov 2020; 19: 14-150
    CrossrefPubMedGoogle Scholar
  • 59 De Clercq E. New nucleoside analogues for the treatment of hemorrhagic fever virus infections. Chem Asian J 2019; 14: 3962-8
    CrossrefPubMedGoogle Scholar
  • 60 McCreary EK, Pogue JM. Coronavirus disease 2019 treatment: A review of early and emerging options. Open Forum Infect Dis 2020; 7: ofaa105
    CrossrefPubMedGoogle Scholar
  • 61 Chen C, Zhang Y, Huang J. et al. Favipiravir versus arbidol for COVID-19: A randomized clinical trial. medRxiv Posted April 15, 2020. Preprint (not peer reviewed). doi: 10.1101/2020.03.17.20037432
  • 62 Chinese Clinical Trial Registry. Available from: http://www.chictr.org.cn/enindex.aspx. [Last accessed 2020 May 11]
  • 63 Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov 2020; 19: 149-50
    CrossrefPubMedGoogle Scholar
  • 64 Lou Y, Liu L, Yao H. et al. Clinical outcomes and plasma concentrations of baloxavir marboxil and favipiravir in COVID-19 patients: An exploratory randomized, controlled trial. medRxiv Posted May 5, 2020. Preprint (not peer reviewed). doi: 10.1101/2020.04.29.20085761
  • 65 Chen I-Y, Moriyama M, Chang M-F, Ichinohe T. Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome. Front Microbiol 2019; 10
    PubMedGoogle Scholar
  • 66 Schoofs T, Klein F, Braunschweig M, Kreider EF, Feldmann A, Nogueira L. et al. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science 2016; 352: 997-1001
    CrossrefPubMedGoogle Scholar
  • 67 U.S. National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/NCT04337359. [Last accessed on 2020 May 1]
  • 68 Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. HLH Across Speciality Collaboration, UK. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395: 1033-4
    CrossrefPubMedGoogle Scholar
  • 69 Giudice V, Pagliano P, Vatrella A, Masullo A, Poto S, Polverino BM. et al. Combination of ruxolitinib and eculizumab for treatment of severe SARS-cov-2-related acute respiratory distress syndrome: A controlled study. Front Pharmacol 2020; 11: 857
    CrossrefPubMedGoogle Scholar
  • 70 Gaspari V, Zengarini C, Greco S, Vangeli V, Mastroianni A. Side effects of ruxolitinib in patients with SARS-cov-2 infection: Two case reports. Int J Antimicrob Agents 2020; 56: 106023
    CrossrefPubMedGoogle Scholar
  • 71 Richardson P, Griffin I, Tucker C. et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 2020; 395: e30-e31
    CrossrefPubMedGoogle Scholar
  • 72 Lilly. Lilly Begins Clinical Testing of Therapies for COVID-19. Press release. Available from: https://investor.lilly.com/news-releases/news-release-details/lilly-begins-clinical-testing-therapies-covid-19. [Last accessed on 2020 Apr 10]
    Google Scholar
  • 73 National Institutes of Health. Coronavirus disease 2019 (COVID-19) Treatment Guidelines. Updated 2020 Jun 11. Available from: https://www.covid19treatmentguidelines.nih.gov/. [Last accessed on 2020 Jun 23]
    Google Scholar
  • 74 Xu X, Han M, Li T. et al. Effective Treatment of Severe COVID-19 Patients with Tocilizumab. Available from: chinaXiv. [Last accessed on 2020 Mar 19]
  • 75 COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Updated 2020 Jun 11. Available from: https://www.covid19treatmentguidelines.nih.gov/. [Last accessed on 2020 Jun 26]
    Google Scholar
  • 76 Aouba A, Baldolli A, Geffray L. et al. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: Case series. Ann Rheum Dis 2020 May 6 [Epub ahead of print]. PMID: 32376597. doi: 10.1136/annrheumdis-2020–217706
  • 77 Huet T, Beaussier H, Voisin O. et al. Anakinra for severe forms of COVID-19: A cohort study. Lancet Rheumatol 2020; 2: e393-e400
    CrossrefPubMedGoogle Scholar
  • 78 Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D. et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: A retrospective cohort study. Lancet Rheumatol 2020; 2: e325-31
    CrossrefPubMedGoogle Scholar
  • 79 Actemra use in Coronavirus Disease 2019 (COVID-19) Standard Reply Letter. South San Francisco, CA: Genentech; 2020
    Google Scholar
  • 80 National Health Commission and State Administration of Traditional Chinese Medicine. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7). (Mandarin; English translation.) 2020 Mar 3
    Google Scholar
  • 81 Haagmans BL, Kuiken T, Martina BE, Fouchier RA, Rimmelzwaan GF, van Amerongen G. et al. Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat Med 2004; 10: 290-3
    CrossrefPubMedGoogle Scholar
  • 82 Lau SKP, Lau CCY, Chan KH, Li CPY, Chen H, Jin DY. et al. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel middle east respiratory syndrome coronavirus: Implications for pathogenesis and treatment. J Gen Virol 2013; 94: 2679-90
    CrossrefPubMedGoogle Scholar
  • 83 Falzarano D, de Wit E, Martellaro C, Callison J, Munster VJ, Feldmann H. Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin. Sci Rep 2013; 3: 1686
    CrossrefPubMedGoogle Scholar
  • 84 Falzarano D, de Wit E, Rasmussen AL, Feldmann F, Okumura A, Scott DP. et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-cov-infected rhesus macaques. Nat Med 2013; 19: 1313-7
    CrossrefPubMedGoogle Scholar
  • 85 Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW. et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011; 52: 447-56
    CrossrefPubMedGoogle Scholar
  • 86 Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL. et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest 2020; 130: 2757-65
    CrossrefPubMedGoogle Scholar
  • 87 Tiberghien P, de Lambalarie X, Morel P. et al. Collecting and evaluating convalescent plasma for COVID-19 treatment: Why and how. VOX 2020. Epub. doi: 10.1111/vox.12926
  • 88 Roback JD, Guarner J. Convalescent plasma to treat COVID-19: Possibilities and challenges. Editorial. JAMA 2020; 323: 1561-62
    CrossrefPubMedGoogle Scholar
  • 89 Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest 2020; 130: 1545-8
    CrossrefPubMedGoogle Scholar
  • 90 Cunningham AC, Goh HP, Koh D. Treatment of COVID-19: Old tricks for new challenges. Crit Care 2020; 24: 91
    CrossrefPubMedGoogle Scholar
  • 91 Madariaga MLL, Guthmiller JJ, Schrantz S. et al. Clinical predictors of donor antibody titer and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial. medRxiv. Available from: (https://www.medrxiv.org/content/10.1101/2020.06.21.20132944v1). [Last accessed on 2020 Jun 23]
  • 92 Zhao JP, Hu Y, Du RH, Chen ZS, Jin Y, Zhou M. et al. [Expert consensus on the use of corticosteroid in patients with 2019-ncov pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi 2020; 43: E007
    PubMedGoogle Scholar
  • 93 Zhou CG, P CH Hersh AR, Caughey AB. Antenatal corticosteroids for pregnant women with COVID-19 infection and preterm prelabor rupture of membranes: A decision analysis. J Mater Fetal Neonatal Med 2020; 1-9
    CrossrefPubMedGoogle Scholar
  • 94 WHO. Clinical Management of Severe Acute Respiratory Infection (SARI) when COVID-19 Disease is Suspected. Interim guidance. Available from: https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf. [Last accessed on 2020 Mar 13].
  • 95 World Health Organization. Clinical Management of COVID-19. Interim guidance. Updated 2020 May 27. Availalbe from: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. [Last accessed on 2020 Jul 1]
    Google Scholar
  • 96 Centers for Disease Control. Healthcare Professionals: Frequently Asked Questions and Answers. Updated 2020 Jun 28. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/faq.html. [Last accessed on 2020 Jul 1]
    Google Scholar
  • 97 Lamontagne F, Rochwerg B, Lytvyn L, Guyatt GH, Møller MH, Annane D. et al. Corticosteroid therapy for sepsis: A clinical practice guideline. BMJ 2018; 362: k3284
    CrossrefPubMedGoogle Scholar
  • 98 Lewis SR, Pritchard MW, Thomas CM. et al. Pharmacological agents for adults with acute respiratory distress syndrome (Review). Cochrane Database Syst Rev 2019; 7: CD004477
    PubMedGoogle Scholar
  • 99 Caly L. et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antivir Res 2020; 178: 104787
    CrossrefPubMedGoogle Scholar
  • 100 Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M. et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020; 56: 105949
    CrossrefPubMedGoogle Scholar
  • 101 Bosseboeuf E, Aubry M, Nhan T, Pina J, Rolain J, Raoult D, Musso D. Azithromycin inhibits the replication of zika virus. J Antivir Antiretroviral 2018; 10: 6-11
    CrossrefGoogle Scholar
  • 102 WHO. Clinical Management of COVID-19. Interim Guidance. Available from: ///C:/Users/hp/Desktop/WHO-2019-nCoV-clinical-2020.5-eng.pdf. [Last accessed on 2020 May 27]
    Google Scholar
  • 103 Simpson RJ, Kunz H, Agha N, Graff R. Exercise and the regulation of immune functions. Prog Mol Biol Trans Sci. 2015; 135: 355-80
    CrossrefPubMedGoogle Scholar
  • 104 Chan KW, Wong VT, Tang SCW. Covid-19: An update on the epidemiological, clinical, preventive, and therapeutic evidence and guidelines of integrative Chinese-western medicine for the management of 2019 novel coronavirus disease. Am J Chin Med 2020; 48: 737-62
    CrossrefPubMedGoogle Scholar
  • 105 National Health Commission Press conference of the joint prevention and control mechanism of the State Council on. Available from: http://www.nhc.gov.cn/xcs/fkdt/202004/05f7318e9fb84b419b35559bc02a42f4.shtml. [Last accessed on 2020 Apr 14]
    Google Scholar
  • 106 WHO. Clinical Management of Severe Acute Respiratory Infection When Novel Coronavirus [nCoV] Infection is Suspected. Available from: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novelcoronavirus-[ncov]-infection-is-suspected. [Last accessed on 2020 Feb 9]
    Google Scholar
  • 107 Arabi YM, Shalhoub S, Mandourah Y, Al-Hameed F, Al-Omari A, Al Qasim E. et al. Ribavirin and interferon therapy for critically ill patients with middle east respiratory syndrome: A multicenter observational study. Clin Infect Dis 2020; 70: 1837-44
    CrossrefPubMedGoogle Scholar
  • 108 Stockman LJ, Bellamy R, Garner P. SARS: Systematic review of treatment effects. PLoS Med 2006; 3: e343
    CrossrefPubMedGoogle Scholar
  • 109 NHC. Guidelines for the Prevention, Diagnosis, and Treatment of Novel Coronavirus-induced Pneumonia. 5th ed. National Health Commission; 2020
    Google Scholar
  • 110 Chang D, Xu H, Rebaza A, Sharma L, Dela Cruz CS. Protecting health-care workers from subclinical coronavirus infection. Lancet Respir Med 2020; 8: e13
    CrossrefPubMedGoogle Scholar
  • 111 Gostic KM, Kucharski AJ, Lloyd-Smith JO. Effectiveness of traveller screening for emerging pathogens is shaped by epidemiology and natural history of infection. Elife 2015; 4: e05564
    CrossrefPubMedGoogle Scholar
  • 112 Corrêa TD. et al. Fluid therapy for septic shock resuscitation: Which fluid should be used?. Einstein 2015; 13: 462-8
    CrossrefPubMedGoogle Scholar
  • 113 Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R. et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med 2017; 43: 304-77
    CrossrefPubMedGoogle Scholar
  • 114 Weiss SL, Peters MJ, Alhazzani W, Agus MSD, Flori HR, Inwald DP. et al. Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. Pediatr Crit Care Med 2020; 21: e52-e106
    CrossrefPubMedGoogle Scholar
  • 115 WHO. Pocketbook of Hospital Care for Children: Guidelines for the Management of Common Childhood Illnesses. Geneva, Switzerland: World Health Organization; 2013
    Google Scholar
  • 116 Bridwell RE, Carius BM, Long B, Oliver JJ, Schmitz G. Sepsis in pregnancy: Recognition and resuscitation. West J Emerg Med 2019; 20: 822-32
    CrossrefPubMedGoogle Scholar